A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata (ALLEGRO-100)

Study type: Clinical Trials Posting date: 07/28/2025 Last updated: 08/11/2025 Status: Recruiting Phase: Phase 3 Country: USA & Canada Eligibility:

12 years old and up; clinical diagnosis of alopecia areata; ≥50% hair loss of the scalp as measured by SALT; current episode of hair loss ≤10 years

Drug: Ritlecitinib Administration: Oral Sponsor: Pfizer Sponsor Link: Click here ClinicalTrials.gov link: Click here Location: Multiple locations in US and Canada

Description:

This study is investigating the safety and effectiveness of ritlecitinib at two different doses, 50 mg and 100mg, in individuals ages 12 and up with severe aloepcia areata.

More information on this trial is available at www.allegro100clinicaltrial.com.